Cargando…
Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
The success of immunotherapy and targeted therapy for metastatic melanoma has generated considerable interest in the adjuvant setting, even though high-risk stage III melanoma (with or without in-transit metastases) still holds a substantial probability of relapse, despite surgical resection and ava...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122306/ https://www.ncbi.nlm.nih.gov/pubmed/34882516 http://dx.doi.org/10.1080/21645515.2021.1971015 |